MM-093, a recombinant human ©-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 6, 2007, Pages 603-610

  Dudich, E ^a  

^a Institute of Immunology   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ABI 001; ALPHA FETOPROTEIN; METHOTREXATE; MM 093; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNE UVEITIS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG SYNTHESIS; HEADACHE; HUMAN; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; UPPER RESPIRATORY TRACT INFECTION; UVEITIS;

ALPHA-FETOPROTEINS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; RECOMBINANT PROTEINS;

EID: 36549081399     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. 399013 Genzyme Transgenics and Atlantic Biopharmaceuticals collaborate on ABI-001. Genzyme Transgenics Corp PRESS RELEASE 2001 February 14
2. 480316 GTC Biotherapeutics announces presentation of a product case study from its external programs at the 2003 Antibody World Summit. GTC Biotherapeutics Inc PRESS RELEASE 2003 February 28
3. 499412 Merrimack's MM-093 enters phase I trials. Merrimack Pharmaceuticals Inc PRESS RELEASE 2003 July 29
4. 513911 Merrimack completes dosing in phase I MM-093 immunomodulator candidate study. Merrimack Pharmaceuticals Inc PRESS RELEASE 2003 November 19
5. 556107 Merrimack's MM-093 phase IIa RA trial completes enrollment. Merrimack Pharmaceuticals Inc PRESS RELEASE 2004 August 25
6. 588067 Merrimack begins phase II RA trial Merrimack Pharmaceuticals Inc PRESS RELEASE 2005 March 03
7. 628428 Merrimack starts MM-093 phase II psoriasis study Merrimack Pharmaceuticals Inc PRESS RELEASE 2005 October 13
8. 662422 Merrimack Pharmaceuticals completes enrollment for phase 2 trial of MM-093 in patients with psoriasis. PRESS RELEASE 2006 April 19
9. 755162 A randomized double-blind, placebo-controlled trial of MM-093, a recombinant version of human α-fetoprotein, in patients with active rheumatoid arthritis (RA). Pollard LC, Murray J, Choy EH ARTHRITIS RHEUM 2005 52 9 S132
10. 780776 Merrimack Pharmaceuticals initiates enrollment in a phase 2 pilot study of MM-093 in patients with autoimmune uveitis. PRESS RELEASE 2007 April 04
11. 784922 Merrimack begins phase II MM-093 trial in RA. Merrimack Pharmaceuticals Inc PRESS RELEASE 2007 April 17
12. 785494 MM-093 lowers rheumatoid factor in moderate to severe rheumatoid arthritis in a multi-center, double-blind, placebo-controlled study of a novel biologic agent produced by transgenic goats. Murray J, Sawitzke A ARTHRITIS RHEUM 2006 54 12 4035
13. 785496 Purification and characterization of a recombinant version of human α-fetoprotein expressed in the milk of transgenic goats. Parker MH, Birck-Wilson E, Allard G, Masiello N, Day M, Murphy KP, Paragas V, Silver S, Moody MD PROTEIN EXPR PURIF 2004 38 2 177-183
14. 785502 A randomized double-blind, placebo-controlled trial of recombinant version of human α-fetoprotein (MM-093) in patients with active rheumatoid arthritis. Pollard LC, Murray J, Moody M, Stewart EJ, Choy EHS ANN RHEM DIS 2007 66 5 687-689
15. 829385 MM-093 is safe and well tolerated in an exploratory phase 2 study and patients with the highest serum levels of MM-093 achieved robust clinical responses. Murray J, Sawitzke A ANN RHEUM DIS 2007 66 Suppl 2 434
16. 829927 Amelioration of autoimmune neuroinflammation by recombinant human α-fetoprotein. Irony-Tur-Sinai M, Grigoriadis N, Lourbopoulos A, Pinto-Maaravi F, Abramsky O, Brenner T EXP NEUROL 2006 198 1 136-144
17. 834230 Chemistry and biology of α-fetoprotein. Deutsch HF ADV CANCER RES 1991 56 253-312
18. 834247 Biological roles of α-fetoprotein during pregnancy and perinatal development. Mizejewski GJ EXP BIOL MED 2004 229 6 439-463
19. 834248 Biological role of α-fetoprotein in cancer: Prospects for anticancer therapy. Mizejewsky GJ 2002 EXPERT REV ANTICANCER THER 2002 2 89-115
20. 834249 Reactivation of the α1-fetoprotein synthesis in systemic lupus erythematosus. Wollina U, Schulze M, Knopf B Z HAUTKR 1985 60 11 902-907
21. 834251 Transactivation of human α-fetoprotein gene by X-gene product of hepatitis B virus in human hepatoma cells. Arima T, Nakao K, Nakata K, Ishikawa H, Ichikawa T, Hamasaki K, Ishii N, Eguchi K INT J MOL MED 2002 9 4 397-400
22. 834252 Downregulation of phorbol 12-myristate 13-acetate-induced tumour necrosis factor-α and interleukin-1β production and gene expression in human monocytic cells by human α-fetoprotein. Wang W, Alpert E HEPATOLOGY 1995 22 3 921-928
23. 834253 Evidence that α-fetoprotein suppresses the immunological function in transgenic mice. Yamashita T, Nakane A, Watanabe T, Miyoshi I, Kasai N BIOCHEM BIOPHYS RES COMMUN 1994 201 3 1154-1159
24. 834280 Evidence that immunosuppression is an intrinsic property of the α-fetoprotein molecule. Semeniuk DJ, Boismenu R, Tam J, Weissenhofer W, Murgita RA ADV EXP MED BIOL 1995 383 255-269
25. 834303 α-Fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-caspase interaction. Dudich E, Semenkova L, Dudich I, Denesyuk A, Tatulov E, Korpela T FEBS J 2006 273 16 3837-3849
26. 834317 α-Fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation. Semenkova L, Dudich E, Dudich I, Tokhtamisheva N, Tatulov E, Okruzhnov Y, Garcia-Foncillas J, Palop-Cubillo JA, Korpela T EUR J BIOCHEM 2003 270 21 4388-4399
27. 834318 α-Fetoprotein impairs APC function and induces their apoptosis. Um SH, Mulhall C, Alisa A, Ives AR, Karani J, Williams R, Bertoletti A, Behboudi S J IMMUNOL 2004 173 3 1772-1778
28. 834319 Pregnancy and multiple sclerosis. Abramsky O ANN NEUROL 1994 36 Suppl S38-S41
29. 834321 Rheumatoid arthritis and pregnancy. Nicholas NS, Panayi GS CLIN EXP RHEUMATOL 1988 6 2 179-182
30. 834322 Novel approaches to treatment of autoimmune neuroinflammation and lessons for drug development. Nizri E, Irony-Tur-Sinai M, Grigoriadis N, Abramsky O, Amitai G, Brenner T PHARMACOLOGY 2007 79 1 42-49
31. 834323 Fine specificity analysis of an HLA-A2.1-restricted immunodominant T-cell epitope derived from human α-fetoprotein. Meng WS, Butterfield LH, Ribas A, Heller JB, Dissette VB, Glaspy JA, McBride WH, Economou JS MOL IMMUNOL 2000 37 16 943-950
32. 834325 Cellular and genetic restrictions in the immunoregulatory activity of α-fetoprotein. III. Role of the MLC-stimulating cell population in α-fetoprotein-induced suppression of T-cell-mediated cytotoxicity. Peck AB, Murgita RA, Wigzell H J IMMUNOL 1982 128 3 1134-1140
33. 834496 Expression of α-fetoprotein receptors by human T-lymphocytes during blastic transformation. Torres JM, Laborda J, Naval J, Darracq N, Calvo M, Mishal Z, Uriel J MOL IMMUNOL 1989 26 9 851-857
34. 834526 Regulation of α-fetoprotein by nuclear factor-κB protects hepatocytes from tumor necrosis factor-α cytotoxicity during fetal liver development and hepatic oncogenesis. Cavin LG, Venkatraman M, Factor VM, Kaur S, Schroeder I, Mercurio F, Beg AA, Thorgeirsson SS, Arsura M CANCER RES 2004 64 19 7030-7038
35. 834528 Regulation and activities α-fetoprotein. Chen H, Egan JO, Chiu JF CRIT REV EUKARYOTIC GENE EXPR 1997 7 1-2 11-41
36. 834529 Primary structures of human α-fetoprotein and its mRNA. Morinaga T, Sakai M, Wegmann TG, Tamaoki T PROC NATL ACAD SCI USA 1983 80 15 4604-4608
37. 834531 Expression of human α-fetoprotein in yeast. Yamamoto R, Sakamoto T, Nishi S, Sakai M, Morinaga T, Tamaoki T LIFE SCI 1990 46 23 1679-1686
38. 834532 Expression of rat α-fetoprotein cDNA in Escherichia coli and in yeast. Nishi S, Koyama Y, Sakamoto T, Soda M, Kairiyama CB J BIOCHEM 1988 104 6 968-972
39. 834535 Purification and characterization of human and mouse recombinant α-fetoproteins expressed in Escherichia coli. Boismenu R, Semeniuk D, Murgita RA PROTEIN EXPR PURIF 1997 10 1 10-26
40. 834536 Similarity between natural and recombinant human α-fetoprotein as inhibitors of estrogen-dependent breast cancer growth. Bennett JA, Semeniuk DJ, Jacobson HI, Murgita RA BREAST CANCER RES TREAT 1997 45 2 169-179
41. 834537 The refolding of different α-fetoprotein variants. Leong SS, Middelberg AP PROTEIN SCI 2006 15 9 2040-2050
42. 834538 Characterization of sugar chain structures of human α-fetoprotein by lectin affinity electrophoresis. Taketa K ELECTROPHORESIS 1998 19 15 2595-2602
43. 834539 Human α-fetoprotein binds to primary macrophages. Atemezem A, Mbemba E, Marfaing R, Vaysse J, Pontet M, Saffar L, Charnaux N, Gattegno L BIOCHEM BIOPHYS RES COMMUN 2002 296 3 507-514
44. 834540 Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP ARTHRITIS RHEUM 2006 54 8 2368-2376
45. 834542 Immediate hypersensitivity to corticosteroids: Finding an alternative. Rodrigues-Alves R, Spínola-Santos A, Pedro E, Branco-Ferreira M, Pereira-Barbosa M J INVEST ALLERGOL CLIN IMMUNOL 2007 17 4 284-285
46. 834543 Long lasting side effects of immunosuppressants in children. Monchaud C, Irtan S, Jacqz-Aigrain E ARCH PEDIATR 2007 14 6 599-602
47. 834544 Immunosuppression: Promises and failures. Oger J J NEUROL SCI 2007 259 1-2 74-78
48. 834546 Differentiation of mesenchymal cells derived from human amniotic membranes into hepatocyte-like cells in vitro. Tamagawa T, Oi S, Ishiwata I, Ishikawa H, Nakamura Y HUM CELL 2007 20 3 77-84.
49. 834547 Human hepatic stem cells from fetal and postnatal donors. Schmelzer E, Zhang L, Bruce A, Wauthier E, Ludlow J, Yao HL, Moss N, Melhem A, McClelland R, Turner W, Kulik M et al J EXP MED 2007 204 8 1973-1987
50. 834548 The inhibition of apoptosis by α-fetoprotein (AFP) and the role of AFP receptors in anti-cellular senescence. Laderoute MP, Pilarski LM ANTICANCER RES 1994 14 6B 2429-2438
51. 834551 α-Fetoprotein as a TNF resistance factor for the human hepatocarcinoma cell line HepG2. Semenkova LN, Dudich EI, Dudich IV, Shingarova LN, Korobko VG TUMOR BIOL 1997 18 1 30-40
52. 834552 Growth-regulative activity of human α-fetoprotein for different types of tumor and normal cells. Dudich E, Semenkova L, Gorbatova E, Dudich I, Khromykh L, Tatulov E, Grechko G, Sukhikh G TUMOR BIOL 1998 19 1 30-40
53. 835241 WO-2006009492: Recombinant α-fetoprotein, method and means for preparation thereof, compositions on the base thereof and use thereof. Benevolensky SV, Marchenko AN, Kozlov DG, Zatsepin SS, Shingarova LN, Dudich IV, Semenkova LN, Dudich DI, Tatulov EB, Dudich EI WORLD PATENT 2006 January 26
54. 835478 Randomised double blind, placebo-controlled trial of MM-093, a recombinant version of human αfetoprotein (AFP), in patients with active rheumatoid arthritis (RA). Pollard LC, Murray J, Choy EH RHEUMATOLOGY 2006 45 Suppl 1 Abs 62
55. 835626 NCT00105976: Efficacy study of MM-093 in rheumatoid arthritis patients on methotrexate (MTX). CLINICALTRIALS.GOV 2007 January 17
56. 835628 NCT00458146: A phase 2 study to evaluate the efficacy and safety of 60mg of MM-093 in patients with active rheumatoid arthritis. CLINICALTRIALS.GOV 2007 May 24
57. 835629 NCT00147329: Safety and efficacy study of MM-093 in patients with chronic plaque psoriasis. CLINICALTRIALS.GOV 2007 February 21
58. 835632 NCT00444743: Phase 2 study of MM-093 to treat patients with uveitis. CLINICALTRIALS.GOV 2007 March 23
59. 836360 Treatment of experimental allergic encephalomyelitis in rabbits with α-fetoprotein. Brenner T, Evron S, Soffer D, Abramsky O ISR J MED SCI 1985 12 21 945-949
60. 841022 Receptor-mediated endocytosis and recycling of α-fetoprotein in human B-lymphoma and T-leukemia cells. Torres JM, Geuskens M, Uriel J INT J CANCER 1991 47 1 110-117
61. 841024 A study, by electron microscopy, of the specific uptake of α-fetoprotein by mouse embryonic fibroblasts in relation to in vitro aging, and by human mammary epithelial tumor cells in comparison with normal donor's cells. Geuskens M, Dupressoir T, Uriel J J SUBMICROSC CYTOL 1992 23 59-66
62. 841026 Specific maternal anti-fetal lymphoproliferative responses and their regulation by natural immunosuppressive factors. Hoskin DW, Murgita RA CLIN EXP IMMUNOL 1989 76 2 262-267
63. 841027 Suppression by α-fetoprotein of murine natural killer cell activity stimulated in vitro and in vivo by interferon and interleukin 2. Cohen BL, Orn A, Gronvik KO, Gidlund M, Wigzell H, Murgita RA SCAND J IMMUNOL 1986 23 2 211-223
64. 841028 α-Fetoprotein derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts. Bennett JA, Zhu S, Pagano-Mirarchi A, Kellom TA, Jacobson HI CLIN CANCER RES 1998 4 11 2877-2884
65. 841030 Age-dependent growth inhibition of estrogen-sensitive rat mammary tumors. Probable role of α-fetoprotein. Sonnenschein C, Ucci AA, Soto AM J NATL CANCER INST 1980 64 5 1141-1146
66. 841031 Purification of α-fetoprotein from human cord serum with demonstration of its antiestrogenic activity. Allen SH, Bennett JA, Mizejewski GJ, Andersen TT, Ferraris S, Jacobson HI BIOCHIM BIOPHYS ACTA 1993 1202 1 135-142
67. 841032 Growth inhibition of estrogen-sensitive rat mammary tumors. Effect of an α-fetoprotein-secreting hepatoma. Sonnenschein C, Ucci AA, Soto AM J NATL CANCER INST 1980 64 5 1147-1152
68. 841033 Isolation and properties of human α-fetoprotein from HepG2 cell cultures. Deutsch HF, Taniguchi N, Evenson MA TUMOUR BIOL 2000 21 5 267-277
69. 841856 Suppression of primary and secondary autologous mixed lymphocyte reactions by murine α-fetoprotein. Hooper DC, Pagida E, Murgita RA ONCO DEV BIOL MED 1982 3 2-3 151-160